Technological projects portfolio


Development of Live Biotherapeutics for treating IBD

Investment: €555k

Scope: Healthcare

Scientific field(s): Biology and medicinal chemistry

Institution(s): AgroParisTech - Université Paris-Saclay - INRAE - Inserm - AP-HP - Sorbonne Université

Development: Transfer to industrial partner in progress/complete

#LiveBiotherapeutics #IntestinalFlora #IBD


Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are pathologies caused by an imbalance of the gastro-intestinal immune system and an inflammation of the digestive tube wall, in a context where the intestinal flora has been altered.

They manifest through diarrhea and abdominal pain and sometimes the skin or joints are affected as well. IBD affects about 10 million people worldwide, mainly in Western countries, and is becoming increasingly frequent among children.


Patients suffering from IBD present an alteration in the composition and functions of their flora, related to a genetic predisposition and environmental factors (lifestyle, eating habits). The SUCCESS project aims to develop an LBP product (Live Biotherapeutics) using an isolated strain from the gut flora of a healthy person, presenting the capacity to restore a key function of the microbiota that is altered by IBD.

This innovative strategy is an alternative or supplement to current treatments using immunosuppressants, which are only partially effective and associated with potentially serious side effects.


The LBP developed by the SUCCESS project will be used to treat IBD to start. The project will also make it possible to optimize LBP-based therapeutic approaches and intestinal bacteria production for other pathologies related to dysbiosis of the gut flora, such as metabolic syndrome.